Sun Pharma eyes mid-high single digit revenue growth in FY26, bets on innovation

December 26, 2025
Uncategorized

Sun Pharmaceutical Industries targets mid- to high-single digit topline growth in FY26, focusing on innovative medicines and increased R&D investment.

Sun Pharma eyes mid-high single digit revenue growth in FY26, bets on innovation

Leave a ReplyCancel Reply

Stock to watch on February 16: IRB Infra, Torrent Pharma, Ola Electric, NBCC and more

Trade Setup for February 16: Nifty breaches key moving averages; downside risk toward 25,000 looms

Margin ͏trading made safer͏:͏ Understanding HDFC SKY’s 4x leverage model

SEBI looks to curb volatility in Gold and Silver ETFs, proposes to review price band

Manappuram Finance gets RBI’s conditional nod for proposed stake sale to Bain Capital